Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Ho...
Guardado en:
Autores principales: | Levin PA, Nguyen H, Wittbrodt ET, Kim SC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6280559cff2643bda0e3000148b48e08 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Practical combination therapy based on pathophysiology of type 2 diabetes
por: Levin PA
Publicado: (2016) -
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung T, et al.
Publicado: (2015) -
Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
por: Berlie H, et al.
Publicado: (2012) -
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017) -
Optimizing weight control in diabetes: antidiabetic drug selection
por: Kalra S
Publicado: (2010)